Department of Palliative Care and Rehabilitation Medicine, Houston, Texas, USA
Department of Palliative Care and Rehabilitation Medicine, Houston, Texas, USA.
Oncologist. 2018 Feb;23(2):263-270. doi: 10.1634/theoncologist.2017-0248. Epub 2017 Oct 11.
Data on the development and outcomes of effective interventions to address aberrant opioid-related behavior (AB) in patients with cancer are lacking. Our outpatient supportive care clinic developed and implemented a specialized interdisciplinary team approach to manage patients with AB. The purpose of this study was to report clinical outcomes of this novel intervention.
The medical records of 30 consecutive patients with evidence of AB who received the intervention and a random control group of 70 patients without evidence of AB between January 1, 2015, and August 31, 2016, were reviewed.
At baseline, pain intensity ( = .002) and opioid dose ( = .001) were significantly higher among patients with AB. During the course of the study, the median number of ABs per month significantly decreased from three preintervention to 0.4 postintervention ( < .0001). The median morphine equivalent daily dose decreased from 165 mg/day at the first intervention visit to 112 mg/day at the last follow-up ( = .018), although pain intensity did not significantly change ( = .984). "Request for opioid medication refills in the clinic earlier than the expected time" was the AB with the highest frequency prior to the intervention and the greatest improvement during the study period. Younger age ( < .0001) and higher Edmonton Symptom Assessment System anxiety score ( = .005) were independent predictors of the presence of AB.
The intervention was associated with a reduction in the frequency of AB and opioid utilization among patients with cancer receiving chronic opioid therapy. More research is needed to further characterize the clinical effectiveness of this intervention.
There are currently no well-defined and evidence-based strategies to manage cancer patients on chronic opioid therapy who demonstrate aberrant opioid-related behavior. The findings of this study offer a promising starting point for the creation of a standardized strategy for clinicians and provides valuable information to guide their practice regarding these patients. The study results will also help clinicians to better understand the types and frequencies of the most common aberrant behaviors observed among patients with cancer who are receiving chronic opioid therapy. This will enhance the process of timely patient identification, management, or referral to the appropriate specialist teams.
缺乏针对癌症患者异常阿片类药物相关行为(AB)的有效干预措施的发展和结果数据。我们的门诊支持护理诊所制定并实施了一种专门的跨学科团队方法来管理 AB 患者。本研究的目的是报告这种新干预措施的临床结果。
回顾了 2015 年 1 月 1 日至 2016 年 8 月 31 日期间接受干预的 30 例 AB 证据连续患者和 70 例无 AB 证据的随机对照组患者的病历。
基线时,AB 患者的疼痛强度( = .002)和阿片类药物剂量( = .001)明显更高。在研究过程中,每月 AB 次数从干预前的 3 次中位数减少到干预后 0.4 次中位数( < .0001)。吗啡当量日剂量中位数从首次干预就诊时的 165mg/天降至最后随访时的 112mg/天( = .018),尽管疼痛强度没有明显变化( = .984)。“要求在预期时间之前在诊所提前补充阿片类药物”是干预前发生频率最高且研究期间改善最大的 AB。年龄较小( < .0001)和较高的埃德蒙顿症状评估系统焦虑评分( = .005)是 AB 存在的独立预测因素。
该干预措施与接受慢性阿片类药物治疗的癌症患者 AB 发生频率和阿片类药物使用减少相关。需要进一步研究以进一步确定该干预措施的临床有效性。
目前尚无明确和循证的策略来管理表现出异常阿片类药物相关行为的接受慢性阿片类药物治疗的癌症患者。本研究的结果为临床医生制定标准化策略提供了一个有希望的起点,并为他们管理这些患者提供了有价值的信息。研究结果还将帮助临床医生更好地了解接受慢性阿片类药物治疗的癌症患者中最常见的异常行为的类型和频率。这将增强及时识别、管理或转介给适当的专科团队的患者的过程。